|Bid||130.00 x 1100|
|Ask||135.35 x 800|
|Day's Range||134.65 - 136.29|
|52 Week Range||103.00 - 149.07|
|Beta (3Y Monthly)||1.18|
|PE Ratio (TTM)||30.67|
|Earnings Date||Nov 5, 2019 - Nov 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||151.92|
Charles River Laboratories International, Inc. today announced that its team of neuroscience drug discovery experts will present 37 scientific posters, both independently and collaboratively with clients, at Neuroscience 2019, the annual meeting of the Society for Neuroscience .
Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter of 2018. Trends reversed 180 degrees during the first half of 2019 amid Powell's pivot and optimistic expectations towards a trade deal with China. Hedge funds and institutional investors tracked by Insider Monkey usually invest a […]
In this article we are going to estimate the intrinsic value of Charles River Laboratories International, Inc...
Managenment believes that under Schechter's term with Paul and John's crucial support, LabCorp (LH) looks well-positioned to grow and thrive in times ahead.
Charles River Laboratories International, Inc. (CRL) announced today that the Company has been selected by Alzheimer’s Research UK to join the Dementia Consortium. The Consortium is a global charity-industry partnership aimed at funding promising research from academia and helping progress projects with the scale and strength of industry supporters. The Consortium invests in academic led research projects, typically 2-3 years in duration, which aim to provide validation of targets for the treatment of dementia or explore the tractability of the target for drug discovery.
Charles River Laboratories International, Inc. (CRL) today announced the appointment of Virginia M. (Gina) Wilson, the recently retired Senior Executive Vice President and Chief Financial Officer of Teachers Insurance and Annuity Association of America (TIAA), to its Board of Directors. Ms. Wilson’s extensive financial management experience across multiple industries will enhance the strategic and financial advisory expertise of Charles River’s Board of Directors. As a member of the Board, she will serve on the Audit Committee and the Corporate Governance and Nominating Committee.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
New EndoScan-V™ endotoxin detection software and Celsis® automated detection platform for rapid sterility introduced to address unmet industry needs
Charles River Laboratories International, Inc. (CRL) announced today that it will present at the Baird 2019 Global Healthcare Conference in New York on Thursday, September 5th, at 10:15 a.m. EDT, and at the Morgan Stanley Global Healthcare Conference in New York on Tuesday, September 10th, at 10:00 a.m. EDT. Charles River will also host a Meeting with Management in New York on Thursday, September 12th, from 8:30 a.m. to 12:30 p.m. EDT. At each of these events, management will present an overview of Charles River’s strategic focus and business developments.
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
If you've received a vaccination, hip replacement or chemotherapy without suffering toxic shock, chances are you've benefited from a vast bloodletting of horseshoe crabs. Swiss biotech Lonza and U.S.-based Charles River Laboratories are the biggest suppliers of crab blood-based endotoxin tests, which detect bacterial contamination in intravenous drugs and medical implants. Meanwhile Charles River, which is still studying rFC, argues moving too quickly could compromise patient safety.
If you've received a vaccination, hip replacement or chemotherapy without suffering toxic shock, chances are you've benefited from a vast bloodletting of horseshoe crabs. Every year, fishermen net hundreds of thousands of the creatures off the U.S. East Coast and in Asia before their prized milky-blue blood is drained for use in medical safety tests. Swiss biotech Lonza and U.S.-based Charles River Laboratories are the biggest suppliers of crab blood-based endotoxin tests, which detect bacterial contamination in intravenous drugs and medical implants.
Charles River (CRL) delivered earnings and revenue surprises of 5.16% and -0.74%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
James Foster became the CEO of Charles River Laboratories International, Inc. (NYSE:CRL) in 1992. This report will...
Does Charles River Laboratories International Inc. (NYSE:CRL) represent a good buying opportunity at the moment? Let’s quickly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on satellite photos and other research activities, so it is no wonder why […]